Abstract 1774P
Background
In a recently published manuscript we demonstrated significant decreases in mental distress, anxiety and depression compared to standard of care following a 6m daily comprehensive program developed with patient engagement. Here we conduct secondary analyses examining the effects of this Prostate Cancer-Patient Empowerment Program (PC-PEP) on patient-reported urinary, bowel, sexual, hormonal and physical function among men scheduled for curative prostate cancer (PC) treatment.
Methods
This crossover randomized clinical trial evaluated 128 men aged 50–82 yr scheduled for curative prostate cancer surgery or radiotherapy (± hormone), 66 received the 6-mo PC-PEP intervention and 62 were randomized to standard of care for 6m and received PC-PEP to the end of the year. PC-PEP comprises regular physical strength and PFMT training, daily dietary advice, bio-feedback stress reduction, and social networking. Weekly online compliance surveys, the International Prostate Symptom Score (IPSS), Expanded Prostate Cancer Index Composite (EPIC), and SF-12 at baseline, 6 and 12m were completed. MLM analyses were used to evaluate the results.
Results
Baseline patient characteristics and outcomes between the two groups were comparable, and weekly compliance for PC-PEP was high among both groups (early v. late intervention). At six months, the PC-PEP group had improved IPSS bother score, EPIC Urinary Incontinence, EPIC Irritative/Obstructive score, physical fitness (lower weight and BMI), SF-12 physical, and mental health function when compared to the control group (p=0.004, p=0.001, p=0.008, p=0.001, p=0.002, and p=0.003 respectively). Analyses revealed that providing the intervention early or late was equally beneficial to patients. No other significant results emerged.
Conclusions
PC-PEP significantly improves lower urinary tract symptoms, physical function and overall quality of life among men scheduled for curative PC treatment compared to standard of care. The program is being currently tested in an international phase 4 trial.
Clinical trial identification
NCT03660085.
Editorial acknowledgement
Legal entity responsible for the study
Nova Scotia Health Authority, Canada.
Funding
Research Nova Scotia Establishment Grant (#2215).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14